The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
Open accessAbstract
CONTEXT: Weekly teriparatide injection at a dose of 56.5 μg has been shown to increase bone mineral density. OBJECTIVE: A phase 3 study was conducted to determine the efficacy of once-weekly teriparatide injection for reducing the incidence of vertebral fractures in patients with osteoporosis. DESIGN AND SETTING: In this randomized, multicenter, double-blind, placebo-controlled trial conducted in Japan, the incidence of morphological vertebral fractures by radiographs was assessed. PATIENTS: Subjects were 578 Japanese patients between the ages of 65 and 95 yr who had prevalent vertebral fracture. INTERVENTION: Subjects were randomly assigned to receive once-weekly s.c. injections of teriparatide (56.5 μg) or placebo for 72 wk. MAIN OUTCOME MEASURE: The primary endpoint was the incidence of new vertebral fracture. RESULTS: Once-weekly injections of teriparatide reduced the risk of new vertebral fracture with a cumulative incidence of 3.1% in the teriparatide group, compared with 14.5% in the placebo group (P < 0.01), and a relative risk of 0.20 (95% confidence interval, 0.09 to 0.45). At 72 wk, teriparatide administration increased bone mineral density by 6.4, 3.0, and 2.3% at the lumbar spine, the total hip, and the femoral neck, respectively, compared with the placebo (P < 0.01). Adverse events (AE) and the dropout rates by AE were more frequently experienced in the teriparatide group, but AE were generally mild and tolerable. CONCLUSION: Weekly s.c. administration of teriparatide at a dose of 56.5 μg may provide another option of anabolic treatments in patients with osteoporosis at higher fracture risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Ross, A. C., Manson, J. E., Abrams, S. A., Aloia, J. F., Brannon, P. M., Clinton, S. K., Durazo-Arvizu, R. A., Gallagher, J. C., Gallo, R. L., Jones, G., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2704 · Cited by 4,026
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035725 · Cited by 829
Orwoll, E., Scheele, W., Paul, S., Adami, S., Syversen, U., Diez-Perez, A., Kaufman, J.-M., Clancy, A., & Gaich, G. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.9 · Cited by 776
Dempster, D. W., Cosman, F., Kurland, E. S., Zhou, H., Nieves, J., Woelfert, L., Shane, E., Plavetić, K., Müller, R., Bilezikian, J., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1846 · Cited by 653
Genant, H. K., Jergas, M., Palermo, L., Nevitt, M., Valentin, R. S., Black, D., & Cummings, S. R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110716 · Cited by 643
Jiang, Y., Zhao, J. J., Mitlak, B. H., Wang, O., Genant, H. K., & Eriksen, E. F. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.1932 · Cited by 616
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
Ettinger, B., Martin, S. J., Crans, G., & Pavo, I. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040117 · Cited by 487
Why the IOM recommendations for vitamin D are deficient
Heaney, R. P., & Holick, M. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.328 · Cited by 376
Body, J.-J., Gaich, G. A., Scheele, W. H., Kulkarni, P. M., Miller, P. D., Peretz, A., Dore, R. K., Correa-Rotter, R., Papaioannou, A., Cumming, D. C., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020334 · Cited by 365
Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6818 · Cited by 360
Chen, P., Satterwhite, J. H., Licata, A. A., Lewiecki, E. M., Sipos, A. A., Misurski, D. M., & Wagman, R. B. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050105 · Cited by 311
Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., Hadji, P., Farrerons, J., Boonen, S., Audran, M., Barker, C., Anastasilakis, A. D., Fraser, W. D., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080506 · Cited by 290
Kurland, E. S. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3069 · Cited by 282
Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate
Cosman, F., Nieves, J., Zion, M., Woelfert, L., Luckey, M., & Lindsay, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050157 · Cited by 250
Zanchetta, Jr., Bogado, C., Ferretti, J., Wang, O., Wilson, M., Sato, M., Gaich, G., Dalsky, G., & Myers, S. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.539 · Cited by 241
Rizzoli, R., Reginster, J.-Y., Boonen, S., Bréart, G., Diez-Perez, A., Felsenberg, D., Kaufman, J.-M., Kanis, J. A., & Cooper, C. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9499-8 · Cited by 206
Hodsman, A. B., Fraher, L. J., Ostbye, T., Adachi, J. D., & Steer, B. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116273 · Cited by 163
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Cosman, F., Lane, N. E., Bolognese, M. A., Zanchetta, J., García-Hernández, P. A., Sees, K. H., Matriano, J. A., Gaumer, K., & Daddona, P. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0358 · Cited by 149
Miyauchi, A., Matsumoto, T., Sugimoto, T., Tsujimoto, M., Warner, M. R., & Nakamura, T. (2010) · Bone · doi:10.1016/j.bone.2010.05.022 · Cited by 146
Self-citationEffects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men
Finkelstein, J. S., Leder, B. Z., Burnett‐Bowie, S. M., Wyland, J. J., Lee, H., de la Paz, A. V., Gibson, K. L., & Neer, R. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0190 · Cited by 138
Boonen, S., Marín, F., Mellström, D., Xie, L., Desaiah, D., Krege, J. H., & Rosen, C. J. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00695.x · Cited by 134
Hodsman, A. B., Kisiel, M., Adachi, J. D., Fraher, L. J., & Watson, P. H. (2000) · Bone · doi:10.1016/s8756-3282(00)00316-1 · Cited by 134
Fujita, T., Inoue, T. M. N., Morii, H., Morita, R., Norimatsu, H., Orimo, H., Takahashi, H. E., Yamamoto, K., & Fukunaga, M. (1999) · Osteoporosis International · doi:10.1007/s001980050151 · Cited by 119
Self-citationGatti, D., Viapiana, O., Idolazzi, L., Fracassi, E., Rossini, M., & Adami, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2552 · Cited by 96
Effects of Teriparatide Retreatment in Osteoporotic Men and Women
Finkelstein, J. S., Wyland, J. J., Leder, B. Z., Burnett‐Bowie, S. M., Lee, H., Jüppner, H., & Neer, R. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0154 · Cited by 80
Saito, M., Marumo, K., Kida, Y., Ushiku, C., Kato, S., Takao-Kawabata, R., & Kuroda, T. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1454-4 · Cited by 75
Prevrhal, S., Krege, J. H., Chen, P., Genant, H. K., & Black, D. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902790993 · Cited by 63
IOM Endorses Vitamin D, Calcium Only for Bone Health, Dispels Deficiency Claims
Slomski, A. J. (2011) · JAMA · doi:10.1001/jama.2011.50 · Cited by 61
Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling
Black, D. M., Bouxsein, M., Palermo, L., McGowan, J., Newitt, D. C., Rosen, E., Majumdar, S., & Rosen, C. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2781 · Cited by 47
Chung, M., Balk, E. M., Ip, S., Lee, J., Terasawa, T., Raman, G., Trikalinos, T. A., Lichtenstein, A. H., & Lau, J. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.29092 · Cited by 28
Cited by
Eastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
Drug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 698
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M. L., Eastell, R., Lui, L.-Y., Wu, L. A., de Papp, A. E., Grauer, A., Marin, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 353
Metadata
- Authors
- Nakamura, T., Sugimoto, T., Nakano, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Yoshikawa, H., Nishizawa, Y., Fujita, T., & Shiraki, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 3097-3106
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1991819568
- Cited by
- 268
- References
- 32
- FWCI
- 20.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.